Pipeline

Ensifentrine (RPL554) is an investigational, first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") that combines bronchodilator and anti-inflammatory activities in one compound. 

In Phase 2 clinical studies in COPD, Ensifentrine has shown significant and clinically meaningful improvements in lung function, symptoms and quality of life as a monotherapy or added onto a maintenance bronchodilator. 

In the Phase 3 ENHANCE-2 clinical trial, Ensifentrine showed significant and clinically meaningful improvements in lung function measures and reduced the rate of COPD exacerbations. Ensifentrine has been well tolerated in clinical trials involving more than 2,200 subjects to date.

AeroFact™ is a nasally inhaled surfactant based on a combination of the long-established bovine lung surfactant Alveofact^® (Lyomark Pharma GmbH, Germany) with a precise and highly efficient nasal delivery system featuring Aerogen's next generation "PDAP™" delivery technology and a touch-screen controller interface. Aerosol delivery of pulmonary surfactant to preterm infants through the nose to the lung is extremely demanding, due to both the technically challenging physical properties of the drug and the difficulties inherent in treatment of such small patients, but is achieved by PDAP, a technical breakthrough based on patented enhancements to the Aerogen group's market-leading aerosol generator technology (www.aerogen.com). 

AeroFact is anticipated to reduce the need for sedation, invasive intubation and mechanical ventilation, all features of current surfactant treatment methods associated with adverse side effects and the potential to exacerbate chronic lung disease in preterm infants.

Bentrio™ Allergy Blocker is a drug-free nasal spray for personal protection against airborne allergens. Upon application into the nose, Bentrio formsa protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of allergens with cells; in addition, the compositionserves to bind such particles and help with their discharge. Together, this is designed to reduce the risk of upper respiratory tract viral infectionsand promote alleviation of allergic symptoms.

Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia at the opioid level, usually in a postoperative setting with the potential benefit of consistent pain relief without the risks associated with opioids, or the disadvantages of bolus short-acting analgesics.